

# SLLK, Control Peptide for TSP1 Inhibitor

Catalog No: tcsc7050



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

464924-27-4

**Formula:**

$C_{21}H_{41}N_5O_6$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O

**Observed Molecular Weight:**

459.58

## Product Description

SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine). Sequence: Ser-Leu-Leu-Lys.

**In Vivo:** TGF-β1 is significantly lower ( $0.10 \pm 0.01$  pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice

receiving SLLK control peptide at day 42 ( $0.20 \pm 0.02$  pg/mL;  $P=0.0001$ ). mRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides<sup>[1]</sup>. Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice<sup>[2]</sup>.

A white rectangular label with the text "SLLK" in bold black font, centered within a light gray rectangular background.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!